Compare Iron Mountain Inc (IRM) vs 10X Genomics Inc (TXG) Price & Performance

Iron Mountain (IRM) trades at $112.97, down 2.38% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong revenue growth from $5.1B in 2022 to $6.9B in 2025, though net margins have compressed from 10.91% to 2.09% over the same period. Recent news highlights expansion in data center capacity and digital partnerships, while institutional investors show mixed positioning with significant options activity.

The stock presents a growth story with data center expansion driving revenue, but faces headwinds from high debt levels (79.04% debt-to-asset ratio) and margin pressure. Analyst consensus remains bullish with a $142.75 price target representing 26% upside, though technical indicators suggest near-term caution. Key risks include interest rate sensitivity and execution challenges in digital transformation initiatives.

10x Genomics (TXG) trades at $77.28, up 1.55% on the day, with a bearish technical signal from moving averages. The company shows improving fundamentals with revenue of $642.82M in 2025 and a reduced net loss of -$43.54M, while recent news highlights strong demand for its Atera spatial biology platform and a patent victory. Positive earnings beats in recent quarters contrast with a high EV/EBITDA of 249.22, indicating significant growth expectations are priced in.

The outlook is mixed; analyst consensus is neutral with a $74.30 price target slightly below the current price, yet operational cash flow turned strongly positive in 2025. Key risks include persistent net losses, high valuation multiples, and execution on new product launches. The stock's near-term direction hinges on Atera's commercial success and achieving profitability.